Centralyze is an Investment Platform for high-value innovative biotechnologies, which aim to addresses major global diseases.
Centralyze builds technology companies around leading research and commerical teams.
We bring confidence to investors by implementing the Centralyze Process: Originate, Engage, Capitalize and Commercialize.
Centralyze performs due diligence of select institutional IP through independent scientific, patent and market analysis.
Centralyze develops with seed investment, commercialization plan development, assignment of IP, corporate structuring and exit partner engagement.
Approved investors are invited to invest in the equity of our portfolio companies.
Milestone-based investment allows for a broad range of investors to come in at their preferred research stage and risk level.
Our portfolio companies receive back office and ongoing commercialisation support.
Investors are supported by company oversight, reporting and exit opportunity identification as the commercialisation concludes.
Upon successful completion of their commercialisation plan, each portfolio company is exited, whether it be a pharmaceutical company, venture capital, or through an IPO.